Papzimeos™ (zopapogene imadenovec-drba)

Papzimeos (zopapogene imadenovec-drba) is covered for FDA‑indicated treatment of recurrent respiratory papillomatosis in adults (≥18) with biopsy‑confirmed diagnosis; patients under 18 or without required documentation do not meet coverage. Coverage requires a debulking procedure performed or planned prior to administration, prescription by or consultation with a pulmonologist, oncologist, thoracic surgeon, or otolaryngologist, documentation of age/biopsy/debulking/specialist involvement, and adherence to the subcutaneous dosing regimen of 5×10^11 PU per dose given as four injections over 12 weeks (second at 2 weeks, third at 6 weeks, fourth at 12 weeks) with approval limited to 4 doses (3 months).

"Treatment of adults with recurrent respiratory papillomatosis (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.